MADISON, Wis. – Propeller Health has raised $20M in funding to advance its line of digital therapeutics and connected devices for the treatment of chronic respiratory disease. “With our industry-leading platform and in partnership with our growing Propeller Provider Network, we now have the foundation in place to bring the benefits of digital medicines to many new conditions,” said David Van Sickle, co-founder and CEO of Propeller Health, in a statement. The funding round was led by Aptar Pharma, which is also partnering with Propeller to work with pharmaceutical brands to co-develop and co-market digital medicines across therapeutic areas, leveraging Aptar Pharma’s expertise in device development, packaging innovation and quality manufacturing. “We believe this approach will provide significant value to patients, health care providers, payers and our pharma company partners,” said Salim Haffar, president of Aptar Pharma, in a statement.
You are here: / / Propeller Health raises $20M, announces partnership with Aptar Pharma